Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan Sells 27,600 Shares of Stock

Pediatrix Medical Group, Inc. (NYSE:MD) Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total transaction of $423,660.00. Following the transaction, the director now owns 138,683 shares of the company’s stock, valued at $2,128,784.05. This trade represents a 16.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Pediatrix Medical Group Stock Performance

Pediatrix Medical Group stock traded down $0.16 during mid-day trading on Friday, hitting $14.60. 43,385 shares of the company were exchanged, compared to its average volume of 864,096. The company has a debt-to-equity ratio of 0.83, a quick ratio of 1.42 and a current ratio of 1.42. The business has a fifty day moving average of $12.46 and a 200 day moving average of $9.81. Pediatrix Medical Group, Inc. has a 1-year low of $6.62 and a 1-year high of $16.41.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Friday, November 1st. The company reported $0.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a positive return on equity of 12.79% and a negative net margin of 12.65%. The firm had revenue of $511.20 million during the quarter, compared to analyst estimates of $498.87 million. During the same period in the prior year, the company posted $0.29 earnings per share. The business’s revenue for the quarter was up .9% compared to the same quarter last year. Equities analysts predict that Pediatrix Medical Group, Inc. will post 1.25 EPS for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have commented on MD. Truist Financial upped their price objective on shares of Pediatrix Medical Group from $13.00 to $16.00 and gave the stock a “hold” rating in a research report on Monday, November 4th. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday. UBS Group raised their target price on Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a research note on Tuesday, November 5th. Jefferies Financial Group boosted their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the stock a “buy” rating in a research report on Tuesday, November 5th. Finally, Deutsche Bank Aktiengesellschaft upped their target price on Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a report on Monday, November 4th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $16.10.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP increased its stake in shares of Pediatrix Medical Group by 797.0% in the second quarter. Rubric Capital Management LP now owns 8,150,000 shares of the company’s stock valued at $61,532,000 after buying an additional 7,241,400 shares in the last quarter. Dana Investment Advisors Inc. increased its stake in shares of Pediatrix Medical Group by 80.3% in the second quarter. Dana Investment Advisors Inc. now owns 1,023,136 shares of the company’s stock valued at $7,725,000 after buying an additional 455,785 shares in the last quarter. Boston Partners increased its stake in shares of Pediatrix Medical Group by 34.0% in the first quarter. Boston Partners now owns 1,786,434 shares of the company’s stock valued at $17,702,000 after buying an additional 453,254 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in Pediatrix Medical Group by 639.4% in the second quarter. Cubist Systematic Strategies LLC now owns 290,336 shares of the company’s stock valued at $2,192,000 after acquiring an additional 251,072 shares during the last quarter. Finally, ClariVest Asset Management LLC bought a new position in Pediatrix Medical Group in the second quarter valued at about $1,721,000. 97.71% of the stock is currently owned by institutional investors and hedge funds.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.